Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Novo Nordisk (NVO - Analyst Report) recently announced that the US Court of Appeals for the Federal Circuit has found the patent on its diabetes drug, Prandin (repaglinide), to be invalid.

Novo Nordisk holds a patent for the combination of Prandin and metformin for the treatment of type II diabetes. In the US, the patent for Prandin has expired while the patent for PrandiMet will expire in 2018.

The US Court of Appeals for the Federal Circuit partially affirmed the district court’s decision, with a two-to-one ruling, finding the patent to be invalid. This will pave the way for the introduction of generic versions of Prandin. The Court of Appeals, however, unanimously reversed the ruling regarding Novo Nordisk committing inequitable conduct at the time of acquiring the patent.

Novo Nordisk had filed a patent infringement lawsuit against Caraco Pharmaceutical Laboratories, Ltd. in the US District Court for the Eastern District of Michigan, in Jun 2005. The lawsuit was regarding Caraco’s abbreviated new drug application (ANDA) for the generic version of Prandin. In Jan 2011, the district court held this patent invalid and unenforceable. Instantly, Novo Nordisk appealed this decision to the US Court of Appeals for the Federal Circuit.

Apart from Caraco Pharma, Novo Nordisk has filed patent infringement lawsuits against three other companies, namely, Paddock Laboratories, Aurobindo Pharma Ltd. and Novartis’s (NVS - Snapshot Report) generic division, Sandoz.

Novo Nordisk still believes in the validity of its patent and will provide an update on it at the time of announcing financial results for the first six months of 2013, on Aug 8.

Combined US sales of the two drugs – Prandin and PrandiMet – were 1.2 billion Danish kroner in 2012.

Novo Nordisk currently carries a Zacks Rank #2 (Buy). Currently, companies like Santarus, Inc. and Jazz Pharmaceuticals plc (JAZZ - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%